Osimertinib (Tagrisso) - Oncology Nurse Advisor
Skip to navigation Skip to main content

Osimertinib (Tagrisso)

Slideshow

  • Osimertinib slide 1

  • Osimertinib slide 2

  • Osimertinib slide 3

  • Osimertinib slide 4

  • Osimertinib slide 5

  • Osimertinib slide 6

  • Osimertinib slide 7

  • Osimertinib slide 8

  • Osimertinib slide 9

  • Osimertinib slide 10

  • Osimertinib slide 11

  • Osimertinib slide 12

  • Osimertinib slide 13

  • Osimertinib slide 14

  • Osimertinib slide 15

  • Osimertinib slide 16

  • Osimertinib slide 17

  • Osimertinib slide 18

  • Osimertinib slide 19

  • Osimertinib slide 20

  • Osimertinib slide 21

  • Osimertinib slide 22

  • Osimertinib slide 23

  • Osimertinib slide 24

  • Osimertinib slide 25

  • Osimertinib slide 26

  • Osimertinib slide 27

  • Osimertinib slide 28

  • Osimertinib slide 29

This slideshow reviews osimertinib (Tagrisso), indicated for HFirst-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations.

Table of Contents

Slide 4: Dosage and Administration
Slide 14: Cautions, Effects, and Interactions
Slide 22: What to Tell Your Patient
Slide 29: Reference 

Topics:

Drug Information Slideshows Stat Consult
Next hm-slideshow in Slides